Discovering Tomorrow’s Medicines Today

Dr. Sophie Venet (pictured) closely examines the telltale tracks of a culture sample in a petri dish. Welcome to Novimmune! A Swiss biotech company focused
on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer.

Breakthrough Targeted Medicines

Explore our pipeline of novel antibodies to treat inflammatory and immune-related diseases, cancer, and orphan indications.


World-Class Talent and Experience

Meet some of the people
who have made our scientific research and clinical develop-ment advances possible.


Cutting-Edge Technology Platforms

Peek inside our proprietary technology plaforms which are used to generate monoclonal and bispecific antibodies.


Helping Patients
Heal Themselves

Discover how the human immune system works and how antibody drug therapy can help restore patient health.

NEWS: Novimmune’s New Rheumatoid Arthritis Drug Clears Regulatory Hurdles
Novimmune announced today that it received approvals from the U.S. Food and Drug Administration and the U.K. Medicines and Healthcare products Regulatory Agency to begin testing a new experimental drug in patients with rheumatoid arthritis, or RA.
(2 NOV 2015)

NEWS: Novimmune Announces Presentations at 2015 American College of Rheumatology (ACR) Annual Meeting
Novimmune announced plans for several presentations at the upcoming 2015 Annual Meeting of the American College of Rheumatology (ACR) in San Francisco, California on November 6-11.
(2 NOV 2015)

NEWS: Novimmune again sponsors Matthew and Andrew Akin Foundation '700 Miles to Hope' bicycle ride in the U.S.
Novimmune announced that it is a $150,000 Matching Sponsor of the 5th annual Matthew and Andrew Akin Foundation “700 Miles to Hope” bicycle ride, an event the company also sponsored last year.
(14 SEP 2015)

NEWS: Novimmune and Baxalta ink international bispecific antibody collaboration
Novimmune SA announced today that it has signed an international research collaboration agreement with Baxalta Incorporated to develop novel bispecific antibodies for an unspecified indication.
(2 SEP 2015)

NEWS: Over 500 race to raise awareness, funds for traumatic disease: '5K to Fight Histio'
More than 400 runners in New York City were joined by an additional 100 virtual participants in several countries to raise awareness of hemophagocytic lymphohistiocytosis, or HLH. Novimmune was a sponsor of this year's 5K event.
(27 JUL 2015)